Korro Bio, Inc.

NASDAQ:KRROHealthcare · Biotechnology

Mkt Cap$176.41M

Float11.69M

Shares O/S14.73M

Inst Own97.9%

Dilution

-0.58%$11.98

AH Close$11.80-1.50%vs close

Mkt Cap$176.41M

Float11.69M

O/S14.73M

Inst Own97.9%

Dilution

NASDAQ:KRRO$11.98-0.58%

MCap$176.41M

Float11.69M

O/S14.73M

Inst Own97.9%

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap$176.41M

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership97.88%

based on 14.73M shares outstanding

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

Country

IPO DateOct 3, 2019

Shares Outstanding14.73M

Float11.69M

Company Overview

Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.

Leadership

Carl P. LeBel, Ph.D.

Chief Development Officer

Christopher R. Loose, Ph.D.

Chief Scientific Officer

David L. Lucchino

Chief Executive Officer, President and Director

Quentin McCubbin

Chief Manufacturing Officer

Employees

Country

Sector

Healthcare

Website

korrobio.com

Analyst Coverage

ConsensusBuy

Price Target

No price targets available

Ratings Distribution

BUY

HOLD

SELL

TOTAL12

Insider Trading

Insider	Title	Type	Shares	Value	Date
FORMELA JEAN FRANCOIS	Director	Sale	31.9K	$450.3K	Sep 14, 2026
FORMELA JEAN FRANCOIS	Director	Sale	6.6K	$93.2K	Sep 14, 2026
Dolan Oliver	Senior Vice President, Finance	Sale	5	$68.58	Sep 11, 2026
FORMELA JEAN FRANCOIS	Director	Sale	1.8K	$24.5K	Sep 11, 2026
FORMELA JEAN FRANCOIS	Director	Sale	8.4K	$118.2K	Sep 11, 2026
Dolan Oliver	Senior Vice President, Finance	Sale	6	$81.62	Sep 9, 2026

Shareholders

97.9%

Institutional

(107)

1.2%

Insiderⓘ

(5)

28.3%

5%+ Owners

(4)

of which 3.7% rests on schedules older than 24 months (1 holder)

Unattributed (incl. retail)ⓘ

Institutional97.9%

Insider1.2%

5%+ Beneficial28.3%

Top Shareholders

Name	Shares	%	Source
Invus Public Equities, L.P. 2 · may incl. warrants· filed Jul 2024	41.3M	4.5% as filed	13G
Lynx1 Capital Management LP	1.5M	10.4%	13F
Venrock Healthcare Capital Partners III, L.P. · may incl. warrants· reaffirmed 13F Aug 2026	1.5M	10.1%	13G
New Enterprise Associates 17, L.P. · may incl. warrants· filed Mar 2026	1.4M	9.7%	13D
NEA Management Company, LLC	1.3M	8.8%	13F
Venrock Adviser, LLC	1.0M	6.9%	13F
Atlas Venture Life Science Advisors, LLC	962.9K	6.5%	13F
BALYASNY ASSET MANAGEMENT L.P.	951.8K	6.5%	13F
BlackRock, Inc.	817.6K	5.6%	13F
Lynx1 Capital Management LP · also on 13F· may incl. warrants· filed Jan 2026	733.6K	5.0%	13G